Travere Therapeutics (TVTX) total liabilities

Total liabilities · fiscal 2025
$490.36M

Travere Therapeutics (TVTX) had total liabilities of $490.36M at the end of fiscal 2025 (December 31, 2025). That is 8.4% lower than the $535.05M of fiscal 2024. Figures as of 19 Nov 2026, 03:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$490.36M
Change on fiscal 2024
−8.4%
Growth, 5 years
+4.4% a year
Growth, 10 years
+8.7% a year
Highest on record
$629.73Mfiscal 2022
Lowest on record
$5.80Mfiscal 2012
Fiscal years on record
142012–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Travere Therapeutics total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 4.4% a year; over ten years the rate was 8.7% a year. Across the 14 fiscal years on record (2012–2025), the highest was $629.73M in fiscal 2022 and the lowest $5.80M in fiscal 2012.

History · 14 fiscal years

Total liabilities by fiscal year

Travere Therapeutics total liabilities, year by year

Travere Therapeutics (TVTX) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$490.36M 8.4% down
2024$535.05M 9.0% down
2023$588.10M 6.6% down
2022$629.73M 32.7% up
2021$474.52M 19.8% up
2020$396.23M 3.3% up
2019$383.60M 1.9% down
2018$390.91M 72.0% up
2017$227.21M 4.5% up
2016$217.52M 2.5% up
2015$212.29M 22.9% up
2014$172.72M 330.0% up
2013$40.17M 592.6% up
2012$5.80M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Travere Therapeutics and comparable companies
CompanyTotal liabilitiesFiscal year
MiniMed Group MMED$1.02B2026
Adaptive Biotechnologies ADPT$287.74M2025
Heartflow HTFL$58.81M2025
CRISPR Therapeutics CRSP$343.43M2025
Travere Therapeutics TVTX$490.36M2025
Option Care Health OPCH$2.13B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TVTX

Travere Therapeutics, figure by figure

Travere Therapeutics (TVTX) overview: price, valuation and scorecardAll health care companies by market value

Travere Therapeutics total liabilities: questions and answers

How large are Travere Therapeutics's total liabilities?

Travere Therapeutics (TVTX) had total liabilities of $490.36M at the end of fiscal 2025 (December 31, 2025). That is 8.4% lower than the $535.05M of fiscal 2024.

What is the growth rate of Travere Therapeutics's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 4.4% a year; over ten years the rate was 8.7% a year.

What are the highest and lowest total liabilities figures on record for Travere Therapeutics?

Across the 14 fiscal years on record (2012–2025), the highest was $629.73M in fiscal 2022 and the lowest $5.80M in fiscal 2012.

How is Travere Therapeutics's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Travere Therapeutics it is on record here for 14 fiscal years, 2012 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Travere Therapeutics (TVTX) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/TVTX/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.